Enterprise Value
-8.36M
Cash
16.82M
Avg Qtr Burn
-6.20M
Short % of Float
1.03%
Insider Ownership
5.13%
Institutional Own.
11.18%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WP1066 (p-STAT3 inhibitor) Details Solid tumor/s, Cancer, Brain tumor, Glioblastoma | Phase 2 Data readout | |
WP1122 Details COVID-19 | Phase 2 Update | |
Annamycin Details Solid tumor/s, Cancer, Lung Metastases, Soft tissue sarcoma, Sarcoma | Phase 1/2 Data readout | |
Annamycin + Ara-C Details Cancer, Blood cancer, Acute myeloid leukemia | Phase 1/2 Update | |
WP1066 (p-STAT3 inhibitor) Details Cancer, Brain tumor, Solid tumor/s, Glioma | Phase 1/2 Initiation | |
WP1220 Details Cancer, T-cell lymphoma, Cutaneous T cell lymphoma, Blood cancer | Phase 1 Update |